October 2020

The first clinical trial begins to solve the folding of the liver caused by protein Z

The human trial begins, of the treatment that acts on the liver, due to the protein Alpha-1 Antitrypsin. Almost all cases of AATD are caused by a single mutation in the A1AT gene, known as the ‘Z mutation’. Z Factor, the Cambridge-based drug development company, has administered the first human volunteer ZF874, their novel treatment […]

The first clinical trial begins to solve the folding of the liver caused by protein Z Read More »

The union of two pharmaceutical giants: Takeda and Arrowhead

Takeda and Arrowhead collaborate to develop and commercialize ARO-AAT Takeda and Arrowhead Team Up to Unveil Active Liver, Targeted to the Alpha-1 Community. “This agreement also supports the strategy of selectively partnering to continue investing in the targeted RNAi molecule (TRiMTM) platform”. They also come together to manage the growing portfolio of RNAi therapeutics targeting

The union of two pharmaceutical giants: Takeda and Arrowhead Read More »

Centro Andaluz Alfa-1